207 related articles for article (PubMed ID: 34746691)
21. Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease.
Li BT; Sun M; Li YF; Wang JQ; Zhou ZM; Song BL; Luo J
PLoS Genet; 2020 Aug; 16(8):e1008955. PubMed ID: 32776921
[TBL] [Abstract][Full Text] [Related]
22. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.
Dongiovanni P; Petta S; Maglio C; Fracanzani AL; Pipitone R; Mozzi E; Motta BM; Kaminska D; Rametta R; Grimaudo S; Pelusi S; Montalcini T; Alisi A; Maggioni M; Kärjä V; Borén J; Käkelä P; Di Marco V; Xing C; Nobili V; Dallapiccola B; Craxi A; Pihlajamäki J; Fargion S; Sjöström L; Carlsson LM; Romeo S; Valenti L
Hepatology; 2015 Feb; 61(2):506-14. PubMed ID: 25251399
[TBL] [Abstract][Full Text] [Related]
23. TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD.
Musso G; Cipolla U; Cassader M; Pinach S; Saba F; De Michieli F; Paschetta E; Bongiovanni D; Framarin L; Leone N; Berrutti M; Rosina F; Corvisieri S; Molinaro F; Sircana A; Gambino R
J Lipid Res; 2017 Jun; 58(6):1221-1229. PubMed ID: 28242789
[TBL] [Abstract][Full Text] [Related]
24. Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.
Ehrhardt N; Doche ME; Chen S; Mao HZ; Walsh MT; Bedoya C; Guindi M; Xiong W; Ignatius Irudayam J; Iqbal J; Fuchs S; French SW; Mahmood Hussain M; Arditi M; Arumugaswami V; Péterfy M
Hum Mol Genet; 2017 Jul; 26(14):2719-2731. PubMed ID: 28449094
[TBL] [Abstract][Full Text] [Related]
25. The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis.
Liu Z; Que S; Zhou L; Zheng S; Romeo S; Mardinoglu A; Valenti L
Sci Rep; 2017 Aug; 7(1):9273. PubMed ID: 28839198
[TBL] [Abstract][Full Text] [Related]
26. Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism.
Liu J; Ginsberg HN; Reyes-Soffer G
Curr Opin Lipidol; 2024 Jun; 35(3):157-161. PubMed ID: 38465912
[TBL] [Abstract][Full Text] [Related]
27. PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
Kruk B; Liebe R; Milkiewicz M; Wunsch E; Raszeja-Wyszomirska J; Lammert F; Milkiewicz P; Krawczyk M
PLoS One; 2018; 13(8):e0202942. PubMed ID: 30161167
[TBL] [Abstract][Full Text] [Related]
28. TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children.
Grandone A; Cozzolino D; Marzuillo P; Cirillo G; Di Sessa A; Ruggiero L; Di Palma MR; Perrone L; Miraglia Del Giudice E
Pediatr Obes; 2016 Apr; 11(2):115-9. PubMed ID: 25893821
[TBL] [Abstract][Full Text] [Related]
29. E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6.
Du S; Lu L; Miao Y; Jin W; Li C; Xin Y; Xuan S
Lipids Health Dis; 2017 Apr; 16(1):76. PubMed ID: 28407767
[TBL] [Abstract][Full Text] [Related]
30. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
[TBL] [Abstract][Full Text] [Related]
31. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
[TBL] [Abstract][Full Text] [Related]
32. Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice.
Fan Y; Lu H; Guo Y; Zhu T; Garcia-Barrio MT; Jiang Z; Willer CJ; Zhang J; Chen YE
Gastroenterology; 2016 May; 150(5):1208-1218. PubMed ID: 26774178
[TBL] [Abstract][Full Text] [Related]
33. Effects of TM6SF2 rs58542926 polymorphism on hepatocellular lipids and insulin resistance in early type 2 diabetes.
Bódis K; Bombrich M; Schön M; Knebel B; Zaharia OP; Bönhof G; Karusheva Y; Strassburger K; Kupriyanova Y; Kotzka J; Guthoff R; Schrauwen-Hinderling V; Al-Hasani H; Burkart V; Szendroedi J; Wagner R; Markgraf DF; Roden M;
Nutr Metab Cardiovasc Dis; 2023 Sep; 33(9):1785-1796. PubMed ID: 37495452
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of the association between MBOAT7 rs641738, TM6SF2 rs58542926 and nonalcoholic fatty liver disease susceptibility.
Xia Y; Huang CX; Li GY; Chen KH; Han L; Tang L; Luo HQ; Bao MH
Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):533-541. PubMed ID: 30824369
[TBL] [Abstract][Full Text] [Related]
35. Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population.
Li Y; Liu S; Gao Y; Ma H; Zhan S; Yang Y; Xin Y; Xuan S
BMC Biochem; 2019 Feb; 20(1):3. PubMed ID: 30727943
[TBL] [Abstract][Full Text] [Related]
36. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models.
Longo M; Meroni M; Paolini E; Erconi V; Carli F; Fortunato F; Ronchi D; Piciotti R; Sabatini S; Macchi C; Alisi A; Miele L; Soardo G; Comi GP; Valenti L; Ruscica M; Fracanzani AL; Gastaldelli A; Dongiovanni P
Cell Mol Gastroenterol Hepatol; 2022; 13(3):759-788. PubMed ID: 34823063
[TBL] [Abstract][Full Text] [Related]
37. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
[TBL] [Abstract][Full Text] [Related]
38. The additive effects of the
Chen L; Du S; Lu L; Lin Z; Jin W; Hu D; Jiang X; Xin Y; Xuan S
Oncotarget; 2017 Sep; 8(43):74209-74216. PubMed ID: 29088779
[TBL] [Abstract][Full Text] [Related]
39. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
[TBL] [Abstract][Full Text] [Related]
40. Novel association of
Kim DS; Jackson AU; Li YK; Stringham HM; Kuusisto J; Kangas AJ; Soininen P; Ala-Korpela M; Burant CF; Salomaa V; Boehnke M; Laakso M; Speliotes EK
J Lipid Res; 2017 Jul; 58(7):1471-1481. PubMed ID: 28539357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
